These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 10-year experience with the Biocor porcine bioprosthesis in the mitral position.
    Author: Myken PS, Caidahl K, Larsson S, Berggren HE.
    Journal: J Heart Valve Dis; 1995 Jan; 4(1):63-9. PubMed ID: 7742992.
    Abstract:
    One hundred and thirty-seven consecutive patients had mitral valve replacement between January 1983 and January 1993 with Bicor porcine bioprosthesis. Concomitant cardiac procedures were performed in 37% (51/137). Mean age was 63 years. Follow up was 98% complete at a mean of 53 months. Early mortality was 13% (18/137). Within the 10-year follow up another 34 patients died, 21 due to cardiac and three to valve related causes. Overall survival at 10 years as 54.7 +/- 4.9%, and freedom from valve related mortality 94.9 +/- 2.8%. Functional class improved in all surviving patients with 84% being in NYHA class I or II at the end of the tenth year. There were 10 reoperations, three for structural valve deterioration (SVD), three for non-structural valve dysfunction (non-SVD) and four because of prosthetic valve endocarditis (PVE). Actuarial freedom from reoperation for all causes was 78.9 +/- 9.2%. None of the patients were on long term anticoagulation at hospital discharge but 57% received chronic anticoagulant treatment at the end of the 10-year follow up. Embolism occurred in 13 patients (2.5%/pty, fatal 0.4%/pty). Three patients had anticoagulant related hemorrhage (0.6%/pty, fatal 0.2%/pty). Doppler echocardiography was carried out in 52% within the last three years of follow up. Actuarial freedom from SVD (confirmed at reoperation or by echocardiography) was 80.3 +/- 9.8%. At 10 years 93.2 +/- 2.8% were free from PVE. The incidence of total mortality and morbidity was 5.9%/pty (fatal 0.8%/pty) with an actuarial freedom of 59.6 +/- 8.8% from all valve related complications.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]